European Journal of Nuclear Medicine and Molecular Imaging最新文献

{"title":"First clinical investigation to predict lymphovascular and/or perineural invasion in gastric cancer using 18F-FAPI-42 PET/CT parameters.","authors":"Lilan Fu,Fei Xie,Penghui Sun,Ye Dong,Kemin Zhou,Li Jiang,Ruihe Wu,Yanjiang Han,Hubing Wu,Ganghua Tang,Wenlan Zhou","doi":"10.1007/s00259-025-07325-9","DOIUrl":"https://doi.org/10.1007/s00259-025-07325-9","url":null,"abstract":"OBJECTIVEThis study was conducted to explore the predictive value of PET parameters derived from 18F-FAPI-42 PET/CT in assessing lymphovascular and/or perineural invasion (LVI/PNI) in gastric cancer (GC) patients.METHODS72 GC patients who underwent 18F-FAPI-42 PET/CT prior to surgical resection were included. Clinicopathological factors and PET parameters were collected and analyzed in LVI/PNI-negative and LVI/PNI-positive groups. The predictive value of PET parameters for LVI/PNI status was evaluated using the receiver operating characteristic (ROC) curve. A nomogram was developed using significant predictors from multivariate stepwise regression analysis and its performance was assessed by decision curve analysis (DCA).RESULTSUnivariate analysis indicated a significant association between LVI/PNI status and PET parameters (SUVmax, SUVmean, and TBR) (all p < 0.001). The area under the ROC curve (AUC) values for predicting LVI/PNI were 0.932 [95% CI (0.877-0.987)] for SUVmax, 0.923 [95% CI (0.861-0.984)] for SUVmean, and 0.925 [95% CI (0.865-0.985)] for TBR. The optimal cutoff values for prediction, along with their corresponding sensitivity and specificity, were 3.86 (93.3% and 81.5%) for SUVmax, 2.04 (93.3% and 81.5%) for SUVmean, and 9.75 (91.1% and 81.5%) for TBR. Multivariate analysis identified histological grade and SUVmax as independent risk factors for LVI/PNI prediction. Our nomogram had good discriminatory ability (AUC = 0.934) and offered net benefits in predicting LVI/PNI status by DCA.CONCLUSIONThis study demonstrates that FAPI uptake parameters exhibit an exceptionally high capacity and serve as a noninvasive preoperative tool for predicting LVI/PNI status in GC, with SUVmax emerging as the most suitable predictive indicator.","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"30 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144087741","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Functional intra thoracic kidney due to Bochdalek hernia detected in [18F]FDG PET/CT performed for lung cancer staging.","authors":"Soler Claude,Datry Vincent,Pegard Clothilde,Mathieu Gauthé","doi":"10.1007/s00259-025-07343-7","DOIUrl":"https://doi.org/10.1007/s00259-025-07343-7","url":null,"abstract":"","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"32 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144087743","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Separation of simultaneously acquired [89Zr]atezolizumab and [18F]FDG PET scans.","authors":"Zekai Li,Janneke W de Boer,Tom van Meerten,Anne G H Niezink,Walter Noordzij,Adriaan A Lammertsma,Charalampos Tsoumpas,Adrienne H Brouwers","doi":"10.1007/s00259-025-07340-w","DOIUrl":"https://doi.org/10.1007/s00259-025-07340-w","url":null,"abstract":"","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"54 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144087744","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of baseline 18F-flotufolastat PET bone tumor volume for prognosticating severe hematologic toxicity in patients with metastatic castration-resistant prostate Cancer receiving 177Lu-PSMA-targeted radioligand therapy.","authors":"Amir Karimzadeh,Kimberley Hansen,Stefan Hein,Bernhard Haller,Matthias M Heck,Robert Tauber,Calogero D Alessandria,Matthias Eiber,Isabel Rauscher","doi":"10.1007/s00259-025-07200-7","DOIUrl":"https://doi.org/10.1007/s00259-025-07200-7","url":null,"abstract":"PURPOSEThis retrospective analysis evaluated the prognostic value of baseline 18F-flotufolastat-PET bone tumor metrics for severe hematologic toxicity in metastatic castration-resistant prostate cancer (mCRPC) patients treated with [177Lu]Lu-PSMA-I&T.METHODSData from 182 mCRPC patients with baseline 18F-flotufolastat-PET scans and complete hematologic profiles were analyzed. Bone lesions were semiautomatically delineated, and clinical parameters (e.g., pretreatments, lab results) were assessed. Hematologic adverse events (AEs) were defined per Common Terminology Criteria for Adverse Events version 5.0, with grades 3-4 considered severe. Cox regression was used to identify prognostic factors for AEs.RESULTSBaseline bone tumor volume prognosticated leukocytopenia (HR 1.03 per 100 ml, p = 0.036), while the number of bone lesions was prognostic for anemia (HR 1.04 per 10 lesions, p < 0.001) and severe anemia (HR per 10 lesions 1.05, p = 0.009). Higher baseline hemoglobin correlated with reduced leukocytopenia (HR 0.74, p = 0.002), thrombocytopenia (HR 0.80, p = 0.033), and severe anemia (HR 0.52, p < 0.001). Baseline kidney dysfunction was linked to anemia (HR 2.46, p = 0.002) and severe anemia (HR 3.81, p = 0.023). Prior [223Ra]Radiumdichloride treatment prognosticated severe thrombocytopenia (HR 6.43, p = 0.021).CONCLUSIONBaseline 18F-flotufolastat-PET metrics and pretherapeutic clinical parameters are key prognostic factors for severe hematologic toxicity in mCRPC patients treated with [177Lu]Lu-PSMA-I&T.","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"10 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144087482","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Low-dose temozolomide selectively increases glioblastoma's vascular permeability, tumor microenvironment penetration and the killing potential of systemic actinium-225 α-particle dendrimer-radioconjugates improving treatment efficacy.","authors":"Rajiv Ranjit Nair,Aira Sarkar,Pooja Hariharan,Kathleen L Gabrielson,Tony Wu,Chang Liu,Anjali Sharma,Wathsala Liyanage,Zaver M Bhujwalla,Marie-France Penet Vidaver,Rangaramanujam M Kannan,Stavroula Sofou","doi":"10.1007/s00259-025-07332-w","DOIUrl":"https://doi.org/10.1007/s00259-025-07332-w","url":null,"abstract":"PURPOSEThe poor prognosis of glioblastoma is mostly due to the relatively low tumor vascular permeability to therapeutics, the tumor's vicinity to the brain, that limits treatment aggressiveness, and/or drug resistance.METHODSIn this study, the efficacy of systemically injected actinium-225 dendrimer-radioconjugates was evaluated in an immune-competent orthotopic GL261-C57BL/6 mouse model after administration of low-dose, standard-of-care temozolomide, that selectively increased the tumor vascular permeability to dendrimer-radioconjugates. Alpha-particles' short range in tissue combined with the dendrimers' selective uptake by glioblastomas, could limit the irradiation of the neighboring brain, while the complex double-strand DNA breaks caused by α-particles were expected to be largely impervious to resistance by cancer cells.RESULTSOn mice bearing 9.7 ± 5.7mm3 brain tumors, at activities that did not cause long-term (11-months) toxicities, dendrimer-radioconjugates, that were systemically-administered 24-hours after injection of temozolomide, significantly improved survival compared to dendrimer-radioconjugates alone (44 vs. 39 days mean survival, p = 0.0017) and/or compared to temozolomide alone and/or to non-treated animals (31 and 30 days, p < 0.001). This was attributed to: (1) the noteworthy increase (by 33%) in tumor absorbed doses delivered by dendrimer-radioconjugates when injected after chemotherapy, without altering normal organ (including the brain's) dosimetry; (2) the potentially deeper tumor penetration of dendrimer-radioconjugates, suggested by the enhanced dendrimer penetration within GL261-spheroids, employed as model tumor-avascular regions; and/or (3) the formation of a more lethal cocktail when both modalities acted on same cancer cells.CONCLUSIONSThis study demonstrates the potential and safety of actinium-225 dendrimer-radioconjugates as a systemic α-particle radiotherapy for glioblastoma enhanced by low-dose temozolomide.","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"27 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143945288","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Initial [18F]FDG PET/CT study for survival evaluation of lung transplantation patients with interstitial lung disease.","authors":"Lin Chen,Jing Wang,Chentao Jin,Congcong Yu,Yan Zhong,Xiaofeng Dou,Xiaohui Zhang,Piaopiao Zhang,Juan Chen,Jingyu Chen,Mei Tian,Hong Zhang,Rui Zhou","doi":"10.1007/s00259-025-07315-x","DOIUrl":"https://doi.org/10.1007/s00259-025-07315-x","url":null,"abstract":"PURPOSEThis study aimed to investigate the role of [18F]fluorodeoxyglucose ([18F]FDG) positron emission tomography/computed tomography (PET/CT) in survival prediction of interstitial lung diseases (ILD) patients undergoing lung transplantation (LTx).METHODSEighty-three patients with ILD who underwent LTx were retrospectively included in this study, among whom 43 received unilateral LTx and 40 received bilateral LTx. All the patients received [18F]FDG PET/CT scanning prior to LTx. Clinical characteristics and [18F]FDG PET/CT parameters were analyzed by using univariate and multivariate analysis to identify predictive factors for overall survival (OS). Correlation of post-operative extracorporeal membrane oxygenation (ECMO) time with clinical and [18F]FDG PET/CT parameters was analyzed by using Pearson's correlation analysis.RESULTSPost-operative ECMO time (p < 0.001), age (p = 0.006) and LDH (p = 0.015) were independent predictive factors for OS of unilateral LTx patients. In addition, LDH (p = 0.03) and gender (p = 0.03) were identified as independent factors for OS of bilateral LTx patients. Especially, we found that glucose metabolism (maximum standardized uptake values (SUVmax) of non-transplanted lung, SUVmaxNT) was an independent factor for OS (p = 0.027) of unilateral LTx patients. For patients with bilateral LTx, SUVmin of bilateral lungs exhibited a strong trend in predicting OS (p = 0.08). Furthermore, SUVmean, SUVsum and total lesion glycolysis (TLG) were significantly correlated with post-operative ECMO time.CONCLUSIONThis study for the first time suggested that [18F]FDG PET/CT could be a potential approach in predicting OS of LTx patients with ILD, which might be helpful for the survival evaluation of ILD patients with LTx.","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"13 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143945409","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development of a novel anti-CEACAM5 VHH for SPECT imaging and potential cancer therapy applications","authors":"Ying Cong, Rianne Biemans, Natasja G. Lieuwes, Dennis Suijlen, Philippe Lambin, Ingrid Dijkgraaf, Matthias Bauwens, Ala Yaromina, Ludwig J. Dubois","doi":"10.1007/s00259-025-07321-z","DOIUrl":"https://doi.org/10.1007/s00259-025-07321-z","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Purpose</h3><p>In this study, we investigated the utility of a novel developed anti-CEACAM5 VHH for cancer diagnosis and its potential of being a targeting-moiety of VHH-drug conjugates for cancer therapy.</p><h3 data-test=\"abstract-sub-heading\">Methods</h3><p>Anti-CEACAM5 VHH (6B11) affinity and specific cellular binding was confirmed by ELISA, FACS and immunofluorescence in cancer cell lines with varying CEACAM5 expression levels. Intracellular penetration ability within tumor spheroids was tested with Oregon Green 488 labeled 6B11 (OG488-6B11). Biodistribution and binding specificity of ^99mTc-radiolabeled 6B11 was tested in A549 CEACAM5 overexpressing (A549-CEA5-OV) and knockout (A549-CEA5-KO) tumor-bearing mice upon SPECT/CT imaging, γ-counting and autoradiography. The therapeutic efficacy of 6B11 and 6F8 (anti-CEACAM5 VHH with lower binding affinity) was tested by viability, wound healing and adhesion assays. To verify the potential of VHHs as a warhead for VHH-drug conjugation, an internalization assay with OG488 labeled VHH was performed.</p><h3 data-test=\"abstract-sub-heading\">Result</h3><p>6B11 demonstrated high binding affinity (EC₅₀ 0.5nM) and cellular binding. OG488-6B11 penetrated tumor spheroids completely at 24 h, while a conventional antibody was only visible at the spheroid periphery. SPECT imaging indicated higher uptake (<i>p</i> &lt; 0.05) in A549-CEA5-OV tumors, resulting in increased tumor-to-blood ratios especially at 4 (2.0016 ± 1.1893, <i>p</i> = 0.035) and 24 (2.9371 ± 2.0683, <i>p</i> = 0.003) hpi compared to A549-CEA5-KO tumors at 4 (0.5640 ± 0.3576) and 24 (0.8051 ± 0.4351) hpi. ^99mTc-6B11 was predominantly renally cleared. Autoradiography and immunohistochemistry confirmed these uptake patterns. 6B11 nor 6F8 did exhibit significant anti-cancer therapeutic efficacy in vitro. OG488-6B11 was effectively internalized and accumulated in cells in a time-dependent manner, to end up in the lysosomes.</p><h3 data-test=\"abstract-sub-heading\">Conclusion</h3><p>The anti-CEACAM5 VHH 6B11 is a good candidate for SPECT-based cancer diagnosis and can be potentially used as targeting moiety in the development of VHH-based drug conjugates for cancer treatments.</p><h3 data-test=\"abstract-sub-heading\">Graphical Abstract</h3>","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"123 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143940207","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Post-COVID-19 lung disease: utility of biochemical and imaging markers in uncovering residual lung inflammation and monitoring anti-inflammatory therapy, a prospective study","authors":"Yogita Khandelwal, Manish Ora, Bela Jain, Manish Dixit, Prakash Singh, Ajmal Khan, Alok Nath, Vikas Agarwal, Sanjay Gambhir","doi":"10.1007/s00259-025-07297-w","DOIUrl":"https://doi.org/10.1007/s00259-025-07297-w","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Purpose</h3><p>Post-COVID-19 lung disease (PCLD) is a significant concern following the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic. PCLD encompasses persistent debilitating respiratory symptoms and radiological changes beyond the acute disease phase. It highlights the ongoing search to identify and manage lingering diseases. This prospective study utilizes F18-Fludeoxyglucose (FDG) PET/CT to identify residual inflammatory lung lesions in PCLD. Treatment response was assessed after anti-inflammatory and antifibrotic therapies.</p><h3 data-test=\"abstract-sub-heading\">Materials and methods</h3><p>Thirty patients post-severe COVID-19 pneumonia enrolled. They underwent baseline ¹⁸F-FDG PET/CT scans to unveil residual lung inflammation lesions on FDG and CT. They received antifibrotic (Pirfenidone) and anti-inflammatory (Methylprednisolone) drugs for 6–12 weeks. They were followed up for clinical, biochemical, and imaging treatment responses.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>Baseline ¹⁸F-FDG PET/CT revealed ongoing lung inflammation in all PCLD (mean SUV_max: 3.8 ± 2.3 and number of segments: 8±3 ). The mean CT severity score was 17.7 ± 3.4 with moderate (<i>n</i> = 16) or severe (<i>n</i> = 14) disease involvement. Mild, moderate, and severe ¹⁸F-FDG PET/CT categories were noted in the 8, 14, and 8 patients, respectively. Following treatment, a PET scan showed a significant decrease in disease extent (segments) and severity (FDG uptake) and an improvement in disease grading on imaging (97% of patients). In PET concordance, there was a significant clinical and radiological improvement with a fall in inflammatory markers (<i>p</i> &lt; 0.005). Serum Ferritin and total leukocyte counts were significantly associated with PCLD severity on ¹⁸F-FDG PET/CT(<i>p</i> &lt; 0.05).</p><h3 data-test=\"abstract-sub-heading\">Conclusion</h3><p>This prospective study identifies and quantifies ongoing significant residual lung inflammation in PCLD on ¹⁸F-FDG PET/CT. Anti-inflammatory and antifibrotic drug therapy led to clinical and radiological improvement. ¹⁸F-FDG PET/CT as a non-invasive biomarker helped manage and follow up PCLD patients.</p><h3 data-test=\"abstract-sub-heading\">Clinical trial number</h3><p>Not applicable.</p>","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"13 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143940206","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"18F-FDG PET/CT for predicting prognosis of B-cell non-Hodgkin lymphoma patients treated with chimeric antigen receptor T cells: the value of pre-infusion and M1 image","authors":"Xilan Yao, Hongrong Wang, Xiao Lei, Jialing Cui, Shuang Yao, Jigang Yang","doi":"10.1007/s00259-025-07302-2","DOIUrl":"https://doi.org/10.1007/s00259-025-07302-2","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Purpose</h3><p>We aimed to evaluate the prognostic value of pre- and post-infusion ¹⁸F-FDG PET/CT for B-cell non-Hodgkin lymphoma B-NHL) patients treated with anti-CD19 chimeric antigen receptor T (CAR-T) cells.</p><h3 data-test=\"abstract-sub-heading\">Methods</h3><p>B-NHL patients who received CAR-T therapy and underwent ¹⁸F-FDG PET/CT examination one month before (pre-infusion) and after (M1) CAR-T infusion were collected and regularly followed up. Maximum standardized uptake value (SUVmax), metabolic tumor volume (MTV), total lesion glycolysis (TLG) was recorded for each PET/CT performed, as well as some clinical and laboratory indexes. Progression-free survival (PFS) and overall survival (OS) were endpoints, estimated by the Kaplan-Meier method.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>Ninety-three patients were included. The median follow-up time was 21.1 months. Multivariate analysis showed that extranodal (EN) sites and SUVmax at M1 were independent prognostic factors for PFS. Patients with EN sites ≥ 2 had shorter median PFS than those with EN sites &lt; 2 (6.4 months vs. not reached [NR], <i>P</i> = 0.032). Patients with M1 SUVmax ≥ 12.4 had shorter median PFS than those with SUVmax &lt; 12.4 (1.1 months vs. NR, <i>P</i> &lt; 0.001). Regarding OS, International Prognostic Index (IPI) and SUVmax at M1 were strongly associated with subsequent outcomes. The median OS was 14.1 months for patients with IPI ≥ 3, compared with NR for those with IPI &lt; 3 (<i>P</i> = 0.011). Patients with SUVmax &lt; 12.9 at M1 had longer median OS compared to those with SUVmax ≥ 12.9 (NR vs. 12.0 months, <i>P</i> &lt; 0.001).</p><h3 data-test=\"abstract-sub-heading\">Conclusion</h3><p>For B-NHL patients who received CAR-T therapy, M1 PET/CT had a more important prognostic value than the pre-infusion one. EN sites and SUVmax at M1 were independent risk factors for PFS, and IPI and SUVmax at M1 for OS. Integrating the clinical characteristics and PET/CT parameters can be helpful for early decision-making in patient management.</p><h3 data-test=\"abstract-sub-heading\">Clinical trial number</h3><p>Not applicable.</p>","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"44 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143940208","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Directional interactions from non-small cell lung cancer to brain glucose metabolism revealed by total-body PET imaging","authors":"Tianzheng Zhong, Yanhua Duan, Kun Li, Jianfeng Qiu, Zhaoping Cheng, Weizhao Lu","doi":"10.1007/s00259-025-07324-w","DOIUrl":"https://doi.org/10.1007/s00259-025-07324-w","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Purpose</h3><p>Imaging markers for lung-brain interaction and brain metastasis of non-small cell lung cancer (NSCLC) are lacking. This study aimed to explore the effect of NSCLC on brain glucose metabolism using total-body positron emission tomography (PET) imaging.</p><h3 data-test=\"abstract-sub-heading\">Methods</h3><p>Fifty-six healthy controls (HCs) and 42 NSCLC patients underwent total-body PET imaging. Concentrations of serum tumor markers were obtained for NSCLC patients. Pseudo-time series data of NSCLC were generated based on the tumor, node, metastasis (TNM) staging system. A novel causal metabolic covariance network (CaMCN) between NSCLC and brain glucose metabolism was conducted with maximum and mean of standardized uptake value (SULmax and SULmean), serum tumor markers as the seed series, respectively. Reliability was evaluated by reverse CaMCN analysis. Finally, post-hoc analysis was performed on brain regions that exhibited causality from NSCLC.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>CaMCN analysis demonstrated significant causality from NSCLC to glucose uptake of the posterior fossa regions, the anatomic “watershed areas” and the gray-white matter junction in the frontal, temporal and occipital lobes. Reverse CaMCN analysis demonstrated significant distinctions from the original CaMCN results. Post-hoc analysis revealed that glucose uptake in the inferior temporal gyrus, thalamus, superior frontal gyrus, precentral gyrus and postcentral gyrus exhibited significant differences among HCs and different stages of NSCLC.</p><h3 data-test=\"abstract-sub-heading\">Conclusion</h3><p>The proposed method can capture causal relationships from NSCLC to brain metabolism, providing pathophysiological insights into the lung-brain interaction in NSCLC. Moreover, the identified brain regions were the areas where NSCLC brain metastases frequently occur, holding the promise as biomarkers for brain metastases of NSCLC.</p>","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"118 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143927250","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}